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Abstract
Background: Up to 12% of patients with systemic sclerosis (SSc) have anti-neutrophil cytoplasmic antibodies (ANCA).
However, the majority of these patients do not manifest ANCA-associated vasculitis (AAV) and the significance of ANCA
in these patients is unclear. The aim of this study is to determine the prevalence of ANCA in a well-characterised SSc
cohort and to examine the association between ANCA and SSc clinical characteristics, other autoantibodies, treatments
and mortality.
Methods: Clinical data were obtained from 5 centres in the Australian Scleroderma Cohort Study (ASCS). ANCA
positive was defined as the presence of any one or combination of cytoplasmic ANCA (c-ANCA), perinuclear
ANCA (p-ANCA), atypical ANCA, anti-myeloperoxidase (anti-MPO) or anti-proteinase-3 (anti-PR3). Associations of
demographic and clinical features with ANCA were investigated by logistic or linear regression. Survival analysis
was performed using Kaplan-Meyer curves and Cox regression models.
Results: Of 1303 patients, 116 (8.9%) were ANCA positive. Anti-PR3 was more common than anti-MPO (13.8% and
11.2% of ANCA-positive patients, respectively). Only 3 ANCA-positive patients had AAV. Anti-Scl-70 was more common
in ANCA positive vs ANCA negative (25% vs 12.8%, p < 0.001), anti-MPO positive vs anti-MPO negative (38.5% vs 13.6%,
p = 0.006) and anti-PR3 positive vs anti-PR3 negative patients (44.4% vs 13.4%, p < 0.001). A higher prevalence
of interstitial lung disease (ILD) was found in the ANCA positive (44.8% vs 21.8%, p < 0.001) and the anti-PR3
positive groups (50.0% vs 23.4%, p = 0.009). In multivariable analysis, ANCA-positive status remained associated
with ILD after adjusting for anti-Scl-70 antibodies. Pulmonary embolism (PE) was more common in ANCA-positive
patients (8.6% vs 3.0%, p = 0.002) and anti-PR3-positive patients (16.7% vs 3.3%, p = 0.022). ANCA-positive status
remained associated with PE in a multivariable analysis adjusting for anti-phospholipid antibodies. Kaplan-Meier analysis
revealed increased mortality in ANCA-positive patients (p = 0.006). In Cox regression analysis, ANCA was associated with
increased mortality, after adjusting for age and sex.
Conclusions: ANCA is associated with increased prevalence of ILD and PE in SSc. ANCA should be tested in SSc, as it
identifies individuals with worse prognosis who require close monitoring for adverse outcomes.
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Background
Systemic sclerosis (SSc) is a multisystem autoimmune
disease characterised by a triad of progressive skin and
internal organ fibrosis, autoantibody production and
small vessel vasculopathy [1, 2]. Clinically, SSc patients
are classified as having limited (lcSSc) or diffuse (dcSSc)
SSc, defined by the extent of skin thickening [3].
Abnormal autoantibody production is a characteristic
feature of SSc, and the presence of specific autoanti-
bodies is of prognostic and clinical significance.
Anti-centromere antibodies are classically associated
with lcSSc and pulmonary arterial hypertension (PAH),
while anti-Scl-70 antibodies are more frequently ob-
served in dcSSc and interstitial lung disease (ILD) [4].
Anti-neutrophil cytoplasmic antibodies (ANCA) are
autoantibodies directed against enzymes found within pri-
mary granules of neutrophils and lysosomes in monocytes
and are implicated directly in the pathogenesis of the
small vessel vasculitis [5, 6]. There are three different types
of ANCA, which display distinct patterns under indirect
immunofluorescence (IIF). These are the cytoplasmic pat-
tern (c-ANCA), perinuclear pattern (p-ANCA) and “atyp-
ical” ANCA [5]. c-ANCA directed against proteinase-3
(PR3) is associated with granulomatosis with polyangiitis
(GPA), while p-ANCA is typically directed against myelo-
peroxidase (MPO) and is commonly detected in micro-
scopic polyangiitis (MPA), eosinophilic granulomatosis
with polyangiitis (EGPA) and pauci-immune idiopathic
crescentic glomerulonephritis [7]. In addition, p-ANCA
can be directed against antigens other than MPO and is
observed in a variety of autoimmune disorders including
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), Sjogren’s syndrome (SS), polymyositis (PM) and
dermatomyositis (DM) [8]. Alternative target antigens
for p-ANCA include elastase, lactoferrin, bactericidal/
permeability-increasing protein (BPI) and cathepsin G,
and the pathophysiological significance, and specific
disease associations of these minor target antigens are
unclear [8, 9].
The presence of ANCA in the sera of patients with
SSc is relatively uncommon, with previous studies esti-
mating a prevalence between 0 and 12% [7, 10, 11]. Des-
pite up to 12% of SSc patients having a positive ANCA
titre, only a minority of these patients will develop an
overlap syndrome with AAV. A 2013 review found a
total of only 51 cases of AAV in SSc published in the lit-
erature [10]. A study of 2200 SSc patients found only 8
patients (0.4%) with comorbid AAV and SSc [12]. The
majority of published cases of AAV and SSc overlap de-
scribe MPA or renal-limited vasculitis [10]. Anti-MPO
and p-ANCA are most commonly found, and c-ANCA
positivity and GPA are rarely reported [13].
The underlying features of SSc that are associated with
ANCA and AAV are contentious. AAV has been described
in both lcSSc and dcSSc, with conflicting reports as to
which SSc disease subtype has a higher prevalence of
AAV [13, 14]. Anti-Scl-70 antibodies have been frequently
associated with the development of AAV, with reports of
up to 77% of SSc patients with AAV having anti-Scl-70
antibodies [10, 13, 15]. SSc patients who have overlap syn-
dromes with other connective tissue diseases may have an
increased prevalence of AAV. Case series have suggested
up to 50% of SSc patients with AAV also have clinical fea-
tures of other connective tissue diseases such as SLE [14].
Another consideration is the possibility of drug-in-
duced ANCA or AAV in SSc. Although no longer part
of the therapeutic armamentarium in SSc, D-penicilla-
mine has been associated with the development of
ANCA-associated glomerulonephritis (AAGN) and
some cases of AAGN in SSc may be reflective of prior
D-penicillamine therapy [10, 16–19]. However, it is diffi-
cult to ascertain whether D-penicillamine therapy or SSc
itself is the underlying cause of ANCA production, par-
ticularly in cases where AAGN occurs several years after
cessation of therapy [15, 19].
The clinical significance of ANCA in SSc patients who
do not manifest AAV is controversial. An association be-
tween ANCA in SSc and ILD has been suggested [12,
20–22]. However, this has not been consistently reported
in all case series [15]. It has also been suggested that
ANCA in SSc patients may indicate an inflammatory
component to the illness and that ANCA should be
treated as a “red flag”, prompting a thorough investiga-
tion and follow-up [23]. In the present study, we exam-
ined the clinical significance of ANCA in a large,
well-characterised SSc cohort, including the association
between ANCA and SSc clinical characteristics, auto-
antibodies, treatments and mortality.
Methods
Patients
Patients were recruited from the Australian Scleroderma
Cohort Study (ASCS), a multicentre study of risk and
prognostic factors in SSc across 5 participating Austra-
lian centres (St. Vincent’s Hospital, Melbourne and
Monash Health, Victoria; John Hunter Hospital, New
South Wales; Royal Adelaide Hospital, South Australia;
Fiona Stanley Hospital, Western Australia). All human
research ethics committees of the participating sites have
approved the ASCS. Written informed consent was ob-
tained from all patients at recruitment.
Inclusion and exclusion criteria
We included patients from the ASCS recruited between
January 1, 2007, and May 23, 2016, who fulfilled the
2013 American College of Rheumatology (ACR)/Euro-
pean League Against Rheumatism (EULAR) criteria [24]
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for diagnosis of SSc. Patients with mixed connective tis-
sue disease were excluded from the study.
ANCA testing is routinely performed as part of a
panel of tests requested at entry to the ASCS. Patients
were excluded if they did not have an ANCA result re-
corded in the database. All positive ANCA results were
confirmed by inspection of the original laboratory re-
sults. Patients were excluded if original results were not
available for review. For statistical analyses involving
autoantibodies, patients without a documented autoanti-
body result were excluded from that particular analysis.
ANCA testing
The presence of ANCA was defined by a positive result
for any one or a combination of p-ANCA, c-ANCA,
atypical ANCA, anti-MPO and anti-PR3. Indirect im-
munofluorescence (IIF) was performed using the local
laboratory protocol to detect p-ANCA, c-ANCA and
atypical ANCA. IIF results described as “unable to ex-
clude p-ANCA due to the presence of ANA” were de-
fined as ANCA negative if anti-MPO or anti-PR3 were
negative. Anti-MPO and anti-PR3 were measured by
enzyme-linked immunosorbent assay (ELISA) using the
local laboratory commercial test kit and reference range.
For each ANCA-positive patient, a retrospective case
note review was performed to assess for clinical and histo-
pathological evidence of vasculitis. Cases of ANCA-nega-
tive vasculitis were not explored in this study.
For statistical analysis, patients were divided into
categories based on their ANCA results. Demographics
and clinical manifestations were compared between
ANCA-positive patients and ANCA-negative patients,
anti-MPO-positive patients and anti-MPO-negative pa-
tients, and anti-PR3 positive patients and anti-PR3 nega-
tive patients.
Data collection
Demographic and disease data were prospectively collected
at baseline and at subsequent annual reviews as per a stan-
dardised protocol. All disease features and autoantibodies
were defined as present if they were ever present from the
time of diagnosis. Disease onset and disease duration were
defined from the date of onset of the first non-Raynaud’s
manifestation. Disease subtype was defined as diffuse or
limited as per LeRoy criteria [25]. Patients were diagnosed
with SSc overlap syndrome at physician discretion if fea-
tures of RA, SLE, SS, PM or DM were clinically evident.
Anti-nuclear antibody (ANA) was detected by indirect im-
munofluorescence (IIF) using the local laboratory protocol.
Extractable nuclear antigen (ENA) testing was performed
by ELISA, immunoblot or a combination of these two
methods, using the local laboratory commercial test kits.
Anti-dsDNA testing was performed by ELISA in most
laboratories, with two laboratories using the Farr
radioimmunoassay. ILD was diagnosed on high-resolution-
computed tomography (HRCT) of the chest, which was
performed on the basis of abnormal respiratory function
tests or the presence of crepitations on respiratory system
examination. Pulmonary arterial hypertension (PAH) was
defined by right heart catheterisation as a mean pulmonary
artery pressure ≥ 25mmHg and a pulmonary arterial wedge
pressure ≤ 15mmHg. Scleroderma renal crisis was defined
by a combination of any two of three criteria, which include
new-onset hypertension in the absence of an alternate aeti-
ology, rising creatinine or microangiopathic haemolytic an-
aemia. Small intestinal bacterial overgrowth (SIBO) was
considered present if a patient described concurrent diar-
rhoea and the use of cyclical antibiotics. Gastric antral vas-
cular ectasia (GAVE), reflux oesophagitis and oesophageal
stricture were defined on endoscopy. Data regarding hospi-
talisations were collected annually from patient-reported
admissions for any reason, for a period of greater than 24 h.
Patients were recorded as having had a malignancy if they
reported the presence of any skin, solid organ or haemato-
logical malignancy. Treatments were defined as use ever
from disease onset to the most recent visit. The use of bio-
logics included patients ever being exposed to any of
rituximab, abatacept, tumour necrosis factor (TNF) alpha
inhibitors and tocilizumab.
Statistical analysis
Data are presented as the mean ± standard deviation for
continuous variables and as a number (percentage) for
categorical variables. Univariable analyses of the
relationship between positive ANCA, and positive
anti-MPO and anti-PR3 were conducted using the
chi-squared or Yate’s corrected chi-squared/Fisher’s
exact test (where appropriate) for categorical variables.
The t test or rank sum test (where appropriate) was
utilised for continuous variables. Summary statistics,
univariable and multivariable logistic regression were
performed to determine the correlates of ANCA. Multi-
collinearity and first-order interaction between variables
were taken into consideration when selecting variables
for inclusion in the regression models. Kaplan-Meier
(KM) survival graphs and Cox proportional hazards re-
gression analysis were used to compare survival between
the ANCA-positive and ANCA-negative groups. Statis-
tical significance was defined as p ≤ 0.05. All statistical
analyses were performed using Stata/SE 15.1 software
(StataCorp, College Station, TX, USA).
Results
Study population
A total of 1303 patients fulfilled the inclusion criteria for
this study, and the characteristics of this cohort are sum-
marised in Table 1. Of the 1303 patients included in the
study, 1125 (86.3%) were females, 974 (74.8%) had limited
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disease and 329 (25.2%) had diffuse disease. The majority
of patients were Caucasian (90.4%) followed by Asian
(4.5%). The mean ± standard deviations (SD) of the age of
SSc onset and the age at recruitment were 46.4 ± 14.3 and
57.7 ± 12.5 years, respectively. The median ± interquartile
range (IQR) duration of follow-up was 3.46 ± 2.69 years.
Almost half (49%) of the cohort had ever smoked.
The autoantibody profile of the cohort is summarised
in Table 1. Overall, 93.8% were anti-nuclear antibody
(ANA) positive, 47.0% were anti-centromere positive
and 13.9% were anti-Scl-70 positive. Other autoanti-
bodies with significant prevalence within the cohort
were rheumatoid factor (RF) (25.9%), anti-cardiolipin
(20.1%), RNA polymerase (8.9%) and anti-Ro (6.7%).
Disease features of the cohort are summarised in
Table 1. ILD was present in 311 patients (23.9%), and
163 patients (12.5%) had PAH. Almost half (49.6%) of
patients had digital ulcers, 39.7% had synovitis, 8.6% had
GAVE and 2.7% had a renal crisis. Overlap features with
another connective tissue disease were present in 5.8%,











Age at scleroderma onset, years 46.40 ± 14.26
Age at recruitment, years 57.71 ± 12.54
Disease duration at recruitment, years 11.26 ± 10.31
Duration of follow-up, years 3.46 ± 2.69





Antinuclear antibody 1222 (93.8%)









Anti-beta 2 glycoprotein 94 (7.2%)
Lupus anti-coagulant 35 (2.7%)
Anti-RNA polymerase 116 (8.9%)
Clinical characteristics and complications
Pulmonary arterial hypertension 163 (12.5%)
Interstitial lung disease 311 (23.9%)
Renal crisis 35 (2.7%)
Digital ulcers 646 (49.6%)
SIBO 37 (2.8%)
GAVE 112 (8.6%)
Oesophageal dysmotility 132 (10.1%)




Deep vein thrombosis (DVT) 91 (7.0%)
Table 1 Cohort characteristics (n = 1303) (Continued)
Characteristic Values
Pulmonary embolus (PE) 46 (3.5%)
Overlap features with another connective tissue
disease
76 (5.8%)
Overlap syndrome with rheumatoid arthritis 27 (2.1%)
Overlap syndrome with polymyositis 13 (1.0%)
Overlap syndrome with Sjogren’s 24 (1.8%)
Overlap syndrome with SLE 12 (0.9%)






Calcium channel antagonist 847 (65.0%)





TNF alpha inhibitor 11 (0.8%)
Tocilizumab 5 (0.4%)
Biologics 26 (2.0%)
Values are given as number (%), mean ± SD or median (IQR)
Abbreviations: ANA anti nuclear antibodies, ANCA anti-neutrophil cytoplasmic
antibodies, anti-phospholipid antibodies: any one or combination of anti-cardiolipin,
anti-beta-2-glycoprotein and lupus anticoagulant, anti-dsDNA anti-double stranded
deoxyribonucleic acid, anti-RNP ribonucleoprotein, SIBO small intestinal bacterial
overgrowth, SLE systemic lupus erythematosus, anti-Sm anti-Smith
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and comorbid rheumatoid arthritis was the most com-
mon overlap syndrome, present in 27 patients (2.1%).
Treatment characteristics of the cohort are sum-
marised in Table 1. A significant proportion of the co-
hort had received calcium channel antagonists (65.0%)
and prednisolone (44.5%). With respect to immunosup-
pressive therapies, 8.1% of patients received azathio-
prine, 7.9% had received mycophenolate and 9.1% had
received cyclophosphamide. Only 26 patients (2.0%) had
received biologics.
ANCA-positive vs ANCA-negative groups
Of the cohort of 1303 patients, 116 patients (8.9%) were
ANCA positive, and 1187 (91.1%) were ANCA negative.
Univariable analyses comparing demographic character-
istics between the ANCA-positive and ANCA-negative
groups are summarised in Table 2.
Only 3 ANCA-positive patients had AAV (2.6% of the
ANCA-positive cohort, 0.23% of the entire study cohort).
One patient with AAV had biopsy-proven vasculitis with
mononeuritis multiplex and anti-MPO antibodies. The
second patient had p-ANCA-positive biopsy-proven cres-
centic glomerulonephritis, and the third patient had
anti-MPO antibodies and biopsy-proven focal necrotising
glomerulonephritis.
There was no statistically significant difference in
gender, disease subtype, age of scleroderma onset, dis-
ease duration at recruitment, or duration of follow-up
between ANCA-positive and ANCA-negative groups.
There was a higher proportion of Asian patients in the
ANCA-positive group (12.9% vs 3.7%, p = 0.001).
ANCA-positive patients were less likely to have ever
smoked (36.2% vs 50.3%, p = 0.004).
With respect to autoantibodies, ANCA-positive pa-
tients were more likely to be anti-Scl-70-positive (25.0%
vs 12.8%, p < 0.001) and anti-Ro-positive (11.2% vs 6.2%,
p = 0.040) than ANCA-negative patients.
Anti-centromere antibodies were less common in the
ANCA-positive group (29.3% vs 48.8%, p < 0.001).
Several clinical features were more common in the
ANCA-positive group, including a significantly higher
prevalence of ILD (44.8% vs 21.8%, p < 0.001), synovitis
(54.3% vs 38.2%, p = 0.001), overlap features with an-
other connective tissue disease (12.1% vs 5.2%, p = 0.003)
and overlap features with Sjogren’s syndrome (4.3% vs
1.6%, p = 0.038). ANCA-positive patients were more
likely to have had a pulmonary embolism (8.6% vs 3.0%,
p = 0.002) and malignancy (26.7% vs 18.6%, p = 0.035).
ANCA-positive patients were more likely to be hospita-
lised (49.1% vs 36.5%, p = 0.007).
The ANCA-positive group was more likely to have re-
ceived azathioprine (13.8% vs 7.5%, p = 0.017) and cal-
cium channel antagonists (75.0% vs 64.0%, p = 0.018).
There was a trend towards increased use of prednisolone
and biologics in ANCA-positive patients, but this did
not reach statistical significance.
Anti-MPO-positive vs anti-MPO-negative groups
A total of 13 patients were anti-MPO positive (11.2% of the
ANCA-positive group). Univariable analyses comparing
demographic characteristics between anti-MPO-positive
and anti-MPO-negative patients are summarised in
Table 3.
Demographic characteristics including gender, race,
disease subtype and age of scleroderma onset were simi-
lar between anti-MPO-positive and anti-MPO-negative
groups. For autoantibodies, anti-MPO-positive patients
were more likely to be anti-Scl-70 positive (38.5% vs
13.6%, p = 0.006) and were less likely to be ANA positive
(76.9% vs 93.9%, p = 0.036) than the anti-MPO-negative
group. Anti-MPO-positive patients were more likely to
have an overlap syndrome with rheumatoid arthritis
(15.4% vs 1.9%, p = 0.028). There was a trend towards a
higher prevalence of ILD in the anti-MPO-positive
group, but this did not reach statistical significance
(38.5% vs 23.7%, p = 0.213). There were no other statisti-
cally significant differences in disease features between
anti-MPO-positive and negative groups. Anti-MPO-
positive patients were more likely to receive cyclophos-
phamide (30.8% vs 8.8%, p = 0.023).
Anti-PR3-positive vs anti-PR3-negative groups
A total of 18 patients were anti-PR3 positive (13.8% of the
ANCA-positive cohort). Univariable analyses comparing
demographic characteristics between anti-PR3-positive
and anti-PR3-negative patients are summarised in Table 3.
A higher proportion of male patients (33.3% vs 13.4%,
p = 0.014) and Asian patients (22.2% vs 4.2%, p = 0.024)
were found in the anti-PR3 positive compared to
anti-PR3-negative groups. Other demographic character-
istics including disease subtype, age of scleroderma on-
set, age at recruitment and duration of follow-up were
similar between the two groups.
Anti-PR3-positive patients were more likely to be
anti-Scl-70 positive than the anti-PR3-negative group
(44.4% vs 13.4%, p < 0.001). A significantly higher
prevalence of ILD (50.0% vs 23.4%, p = 0.009) and pul-
monary embolism (16.7% vs 3.3%, p = 0.022) was found
in the anti-PR3-positive group. There was a higher
prevalence of overlap syndrome with rheumatoid arth-
ritis (61.1% vs 39.3%, p = 0.061) and synovitis (11.1% vs
1.9%, p = 0.052) in the anti-PR3-positive group, but this
did not reach statistical significance. A higher propor-
tion of anti-PR3-positive patients had received myco-
phenolate compared to the anti-PR3-negative group
(22.2% vs 7.6%, p = 0.046).
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Female 1028 (86.6%) 97 (83.6%) 0.372
Race
Caucasian 1082 (91.2%) 96 (82.8%)
Asian 44 (3.7%) 15 (12.9%) 0.001#
Aboriginal-Islander 14 (1.2%) 1 (0.9%)
Other 17 (1.4%) 1 (0.9%)
Type of disease
Limited 890 (75.0%) 84 (72.4%)
Diffuse 297 (25.0%) 32 (27.6%) 0.544
Age at scleroderma onset, years 46.43 ± 14.16 45.95 ± 15.74 0.744
Age at recruitment, years 57.73 ± 12.31 57.54 ± 14.72 0.880
Disease duration at recruitment, years 8.29 (13.27) 9.06 (13.84) 0.891^
Duration of follow-up, years 3.07 (4.54) 3.48 (3.48) 0.174^
Ever smoked 597 (50.3%) 42 (36.2%) 0.004
Autoantibodies
Anti-Scl 70 152 (12.8%) 29 (25.0%) < 0.001
Anti-centromere 579 (48.8%) 34 (29.3%) < 0.001
ANA 1115 (93.9%) 107 (92.2%) 0.360
Rheumatoid factor 301 (26.7%) 36 (31.0%) 0.313
Anti-Ro 74 (6.2%) 13 (11.2%) 0.040
Anti-La 17 (1.4%) 3 (2.6%) 0.413#
Anti-RNP 24 (2.0%) 2 (1.7%) > 0.999#
Anti-dsDNA 34 (2.9%) 8 (6.9%) 0.062
Anti-Sm 7 (0.6%) 1 (0.9%) 0.527#
Anti-Jo-1 6 (0.5%) 1 (0.9%) 0.480#
Anti-Scl/PM 14 (1.2%) 1 (0.9%) > 0.999#
Anti-cardiolipin 231 (19.5%) 30 (25.9%) 0.801#
Anti-Beta 2 glycoprotein 83 (7.0%) 11 (9.5%) 0.658
Lupus anticoagulant 31 (2.6%) 4 (3.4%) 0.778#
Anti-RNA polymerase 105 (8.8%) 11 (9.5%) 0.409
Clinical characteristics and complications
Pulmonary arterial hypertension 107 (9.0%) 15 (12.9%) 0.167
Interstitial lung disease 259 (21.8%) 52 (44.8%) < 0.001
Renal crisis 32 (2.7%) 3 (2.6%) > 0.999#
Digital ulcers 587 (49.5%) 59 (50.9%) 0.772
SIBO 35 (2.9%) 2 (1.7%) 0.767#
GAVE 107 (9.0%) 5 (4.3%) 0.085
Oesophageal dysmotility 124 (10.4%) 8 (6.9%) 0.226
Oesphageal stricture 137 (11.5%) 9 (7.8%) 0.218
Synovitis 454 (38.2%) 63 (54.3%) 0.001
Malignancy 221 (18.6%) 31 (26.7%) 0.035
Hospitalised 433 (36.5%) 57 (49.1%) 0.007
Deep vein thrombosis (DVT) 83 (7.0%) 8 (6.9%) 0.969
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Multivariable correlates of ANCA
Variables included in a multivariable model of associa-
tions of ANCA were based on those statistically signifi-
cant in univariable analysis. We excluded “overlap
syndrome with Sjogren’s” due to multicollinearity with
other variables. The final multivariable model included
ILD (OR 2.85, 95% CI 1.92–4.23, p = <0.0001), PE (OR
2.82, 95% CI 1.34–5.95, p = 0.007), overlap syndrome
(OR 2.25, 95% CI 1.19–4.25, p = 0.013) and synovitis
(OR 1.73, 95% CI 1.16–2.56, p = 0.007) (Table 4).
Multivariable analysis of the relationship between ANCA
and interstitial lung disease
In multivariable regression analysis, ANCA was independ-
ently associated with ILD (OR 2.63, 95% CI 1.72–4.0,
p < 0.001) after taking into account anti-Scl-70 antibodies.
Multivariable analysis of the relationship between ANCA
and pulmonary embolism
In multivariable regression analysis, ANCA was independ-
ently associated with pulmonary embolism even after
taking into account the presence of anti-phospholipid
antibodies (OR 3.11, 95% CI 1.49–6.48, p = 0.003).
Survival analysis
Kaplan-Meier analysis comparing survival in ANCA-posi-
tive and ANCA-negative patients (Fig. 1) revealed
ANCA-positive patients had significantly increased mor-
tality (p = 0.006). ANCA remained associated with higher
mortality after adjusting for age at SSc onset and sex
in Cox regression analysis (HR 1.622, 95% CI 1.04–
2.54, p = 0.034).
Discussion
The prevalence of ANCA in this large SSc cohort was
8.9%, which is within the range of 0–12% reported in pre-
vious studies [7, 10, 11]. Previous studies have found
anti-MPO to be the predominant ANCA subtype in SSc.
Comparatively, there was a higher prevalence of anti-PR3
in our cohort (15.5% of ANCA-positive patients) rather
than anti-MPO (11.2% of ANCA-positive patients).






Pulmonary embolus (PE) 36 (3.0%) 10 (8.6%) 0.002
Overlap features with another connective tissue disease 62 (5.2%) 14 (12.1%) 0.003
Overlap syndrome with rheumatoid arthritis 22 (1.9%) 5 (4.3%) 0.076
Overlap syndrome with polymyositis 12 (1.0%) 1 (0.9%) > 0.999#
Overlap syndrome with Sjogren’s 19 (1.6%) 5 (4.3%) 0.038
Overlap syndrome with SLE 9 (0.8%) 3 (2.6%) 0.084#
Overlap syndrome with dermatomyositis 0 (0.0%) 1 (0.9%) 0.089#
Treatments
Prednisolone 520 (43.8%) 60 (51.7%) 0.052
Azathioprine 89 (7.5%) 16 (13.8%) 0.017
Mycophenolate 89 (7.5%) 14 (12.1%) 0.082
Cyclophosphamide 104 (8.8%) 14 (12.1%) 0.236
Ca channel antagonist 760 (64.0%) 87 (75.0%) 0.018
Topical vasodilator 93 (7.8%) 12 (10.3%) 0.343
Iloprost 150 (12.6%) 11 (9.5%) 0.324
Penicillamine 95 (8.0%) 13 (11.2%) 0.232
Rituximab 9 (0.8%) 2 (1.7%) 0.256#
Abatacept 1 (0.1%) 0 (0%) > 0.999#
TNF alpha inhibitor 9 (0.8%) 2 (1.7%) 0.256#
Tocilizumab 4 (0.3%) 1 (0.9%) 0.373
Biologics 21 (1.8%) 5 (4.3%) 0.062
Values are given as number (%), mean ± SD or median (IQR)
Abbreviations: ANA anti nuclear antibodies, ANCA anti-neutrophil cytoplasmic antibodies, anti-phospholipid antibodies: any one or combination of anti-cardiolipin,
anti-beta-2-glycoprotein and lupus anticoagulant, anti-dsDNA anti-double stranded deoxyribonucleic acid, anti-RNP ribonucleoprotein, SIBO small intestinal bacterial
overgrowth, SLE systemic lupus erythematosus, anti-Sm anti-Smith
^Rank sum test
#Fisher’s exact test
Moxey et al. Arthritis Research & Therapy           (2019) 21:57 Page 7 of 12














Female 1115 (86.5%) 9 (69.2%) 0.089# 1112 (86.6%) 12 (66.7%) 0.014
Race
Caucasian 1166 (90.5%) 12 (92.3%) 0.622# 1164 (90.7%) 14 (77.8%) 0.024#
Asian 57 (4.4%) 1 (7.7%) 54 (4.2%) 4 (22.2%)
Aboriginal-Islander 15 (1.2%) 0 (0%) 15 (1.2%) 0 (0%)
Other 18 (1.4%) 0 (0%) 18 (1.4%) 0 (0%)
Type of disease
Limited 966 (74.9%) 8 (61.5%) 0.268 963 (75.0%) 11 (61.1%) 0.178
Diffuse 323 (25.1%) 5 (38.5%) 321 (25.0%) 7 (38.9%)
Age of scleroderma onset, years 46.44 ± 14.27 42.23 ± 14.26 0.290 46.39 ± 14.29 46.86 ± 13.24 0.888
Age at recruitment, years 57.76 ± 12.52 53.07 ± 14.02 0.180 57.71 ± 12.56 58.02 ± 11.17 0.916
Disease duration at recruitment, years 8.31 (12.31) 13.07 (17.33) 0.924^ 8.29 (13.30) 11.31 (16.86) 0.934^
Duration of follow-up, years 3.09 (4.50) 3.36 (3.48) 0.619^ 3.09 (4.50) 3.97 (3.83) 0.640^
Ever smoked 633 (49.1%) 6 (46.2%) 0.832 634 (49.4%) 5 (27.8%) 0.069
Autoantibodies
Anti-Scl-70 175 (13.6%) 5 (38.5%) 0.006 172 (13.4%) 8 (44.4%) < 0.001
Anti-centromere 612 (47.6%) 1 (7.7%) 0.004# 608 (47.4%) 5 (27.8%) 0.092
ANA 1211 (93.9%) 10 (76.9%) 0.036# 1205 (93.8%) 16 (88.9%) 0.285#
Rheumatoid factor 335 (26.0%) 2 (15.4%) 0.532# 333 (25.9%) 4 (22.2%) 0.793#
Anti-Ro 87 (6.7%) 0 (0.0%) > 0.999# 86 (6.7%) 1 (5.6%) > 0.999#
Anti-La 20 (1.6%) 0 (0.0%) > 0.999# 20 (1.6%) 0 (0%) > 0.999#
Anti-RNP 26 (2.0%) 0 (0.0%) > 0.999# 26 (2.0%) 0 (0%) > 0.999#
Anti-dsDNA 41 (3.2%) 1 (7.7%) 0.385# 40 (3.1%) 2 (11.1%) 0.157#
Anti-Sm 8 (0.6%) 0 (0.0%) > 0.999# 8 (0.6%) 0 (0.0%) > 0.999#
Anti-Jo-1 7 (0.5%) 0 (0.0%) > 0.999# 7 (0.5%) 0 (0.0%) > 0.999#
Anti-PM/Scl 15 (1.2%) 0 (0.0%) > 0.999# 15 (1.2%) 0 (0.0%) > 0.999#
Anti phospholipid antibodies 302 (23.4%) 2 (15.4%) > 0.999# 397 (30.9%) 7 (38.9%) 0.105
Anti-cardiolipin 259 (20.1%) 2 (15.4%) > 0.999# 234 (18.2%) 7 (38.9%) 0.600#
Anti-beta 2 glycoprotein 93 (7.2%) 1 (7.7%) 0.539# 93 (7.2%) 1 (5.6%) 0.668#
Lupus anticoagulant 34 (2.6%) 1 (7.7%) 0.226# 35 (2.7%) 0 (0.0%) > 0.999#
Anti-RNA polymerase 113 (8.8%) 3 (23.1%) 0.136# 116 (9.0%) 0 (0.0%) 0.149#
Clinical characteristics and complications
Pulmonary arterial hypertension 121 (9.4%) 1 (7.7%) > 0.999# 118 (9.2%) 4 (22.2%) 0.080#
Interstitial lung disease 305 (23.7%) 5 (38.5%) 0.213 301 (23.4%) 9 (50.0%) 0.009
Renal crisis 35 (2.7%) 0 (0.0%) > 0.999# 35 (2.7%) 0 (0.0%) > 0.999#
Digital ulcers 639 (49.6%) 6 (46.2%) 0.806 635 (49.5%) 10 (55.6%) 0.607
SIBO 37 (2.9%) 0 (0.0%) > 0.999# 37 (2.9%) 0 (0.0%) > 0.999#
GAVE 112 (8.7%) 0 (0.0%) 0.616# 112 (8.7%) 0 (0.0%) 0.393#
Oesophageal dysmotility 130 (10.1%) 1 (7.7%) > 0.999# 130 (10.1%) 1 (5.6%) > 0.999#
Oesphageal stricture 143 (11.1%) 3 (23.1%) 0.171# 145 (11.3%) 1 (5.6%) 0.711#
Synovitis 509 (39.5%) 7 (53.8%) 0.292 505 (39.3%) 11 (61.1%) 0.061
Malignancy 250 (19.6%) 2 (15.4%) > 0.999# 249 (19.4%) 3 (16.7%) > 0.999#
Hospitalised 484 (37.5%) 6 (46.2%) 0.524 481 (37.5%) 9 (50.0%) 0.276
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Given the known association between penicillamine
therapy and the development of ANCA antibodies [10,
16–19], it is notable that in this modern era cohort,
relatively few patients (8.3%) had received penicilla-
mine. In addition, there was no significant difference
in exposure to penicillamine between ANCA positive
and ANCA negative, anti-MPO positive and negative,
and anti-PR3 positive and negative groups. This sug-
gests that exposure to penicillamine is not responsible
for the difference in ANCA status between these
groups.
Overlap syndrome with AAV in our cohort was rare,
with only 3 cases of AAV (0.23% of the entire cohort,
2.6% of ANCA-positive patients). This low prevalence of
AAV is comparable to a previous study of 2200 SSc pa-
tients, which reported a prevalence of AAV of only
0.40% [12]. The reason for the significant majority of
ANCA-positive SSc patients not manifesting vasculitis is
unclear. Theories for this discordance are that the pres-
ence of ANCA is an epiphenomenon of SSc, that ANCA
present in SSc may have poor affinity and avidity for the
epitope and are therefore less pathogenic, that there may















Deep vein thrombosis 89 (6.9%) 1 (7.7%) 0.608# 89 (6.9%) 1 (5.6%) > 0.999#
Pulmonary embolus 44 (3.4%) 1 (7.7%) 0.368# 42 (3.3%) 3 (16.7%) 0.022#
Overlap features with another connective tissue disease 74 (5.7%) 2 (15.4%) 0.173# 74 (5.8%) 2 (11.1%) 0.283#
Overlap syndrome with rheumatoid arthritis 25 (1.9%) 2 (15.4%) 0.028# 25 (1.9%) 2 (11.1%) 0.052#
Overlap syndrome with polymyositis 13 (1.0%) 0 (0.0%) > 0.999# 13 (1.0%) 0 (0.0%) > 0.999#
Overlap syndrome with Sjogren’s 24 (1.9%) 0 (0.0%) > 0.999# 24 (1.9%) 0 (0.0%) > 0.999#
Overlap syndrome with SLE 12 (0.9%) 0 (0.0%) > 0.999# 12 (0.9%) 0 (0.0%) > 0.999#
Overlap syndrome with dermatomyositis 1 (0.1%) 0 (0.0%) > 0.999# 1 (0.1%) 0 (0.0%) > 0.999#
Treatments
Prednisolone 570 (44.2%) 9 (69.2%) 0.093# 568 (44.2%) 11 (61.1%) 0.153
Azathioprine 101 (7.8%) 3 (23.1%) 0.079# 101 (7.9%) 3 (16.7%) 0.169#
Mycophenolate 100 (7.8%) 2 (15.4%) 0.271# 98 (7.6%) 4 (22.2%) 0.046#
Cyclophosphamide 113 (8.8%) 4 (30.8%) 0.023# 113 (8.8%) 4 (22.2%) 0.071#
Calcium channel antagonist 836 (64.9%) 10 (76.9%) 0.364# 833 (64.9%) 13 (72.2%) 0.516
Topical vasodilator 103 (8.0%) 2 (15.4%) 0.283# 103 (8.0%) 2 (11.1%) 0.651#
Iloprost 160 (12.4%) 1 (7.7%) > 0.999# 159 (12.4%) 2 (11.1%) > 0.999#
Operation for peripheral vascular disease 14 (1.1%) 0 (0.0%) > 0.999# 14 (1.1%) 0 (0%) > 0.999#
Penicillamine 105 (8.1%) 3 (23.1%) 0.086# 105 (8.2%) 3 (16.7%) 0.183#
Rituximab 10 (0.8%) 1 (7.7%) 0.105# 10 (0.8%) 1 (5.6%) 0.142#
Abatacept 1 (0.1%) 0 (0.0%) > 0.999# 1 (0.1%) 0 (0%) > 0.999#
TNF alpha inhibitor 11 (0.9%) 0 (0.0%) > 0.999# 11 (0.9%) 0 (0%) > 0.999#
Tocilizumab 5 (0.4%) 0 (0.0%) > 0.999 5 (0.4%) 0 (0%) > 0.999
Biologics ever 25 (1.9%) 1 (7.7%) 0.232# 25 (1.5%) 1 (5.6%) 0.306#
Values are given as number (%), mean ± SD or median (IQR)
Abbreviations: ANA anti nuclear antibodies, ANCA anti-neutrophil cytoplasmic antibodies, anti-phospholipid antibodies: any one or combination of anti-cardiolipin,
anti-beta-2-glycoprotein and lupus anticoagulant, anti-dsDNA anti-double stranded deoxyribonucleic acid, anti-RNP ribonucleoprotein, SIBO small intestinal
bacterial overgrowth, SLE systemic lupus erythematosus, anti-Sm anti-Smith
^Rank sum test
#Fisher’s exact test
Table 4 Multivariable logistic regression analysis for clinical
correlates of ANCA
Clinical characteristic OR 95% CI p
ILD 2.85 1.91–4.23 <0.0001
Pulmonary embolism 2.82 1.34–5.95 0.007
Overlap syndrome 2.25 1.19–4.25 0.013
Synovitis 1.72 1.16–2.56 0.007
Abbreviations: ILD interstitial lung disease
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be false positive ANCA results or that ANCA has been
detected prior to the future onset of AAV [8].
There were several differences in demographics between
ANCA-positive and ANCA-negative patients. ANCA-
positive patients were more likely to be Asian, and this dif-
ference was also observed in the anti-PR3-positive group
compared to the anti-PR3-negative cohort. A higher pro-
portion of male patients were found in the anti-PR3-posi-
tive group, which is notable given that SSc male patients
have been shown to have a higher prevalence of ILD and
increased mortality [26].
Limited disease predominated in our entire cohort
(74.8%) and in both the ANCA-positive and ANCA-nega-
tive groups. Despite a predominance of lcSSc in all groups,
there was a significantly higher prevalence of anti-Scl-70
in the ANCA-positive group compared to the
ANCA-negative group, the anti-MPO-positive group
compared to the anti-MPO-negative group, and the
anti-PR3-positive group compared to the anti-PR3-nega-
tive group. Accordingly, as these antibodies are mutually
exclusive, there was also a lower prevalence of
anti-centromere antibodies in the ANCA-positive, anti-
MPO-positive and anti-PR3-positive groups. There was a
significantly lower prevalence of anti-nuclear antibody in
the anti-MPO-positive group.
There was a significantly higher prevalence of ILD in
the ANCA positive compared to ANCA-negative group
and also the anti-PR3-positive group compared to the
anti-PR3-negative group. Importantly, in multivariable
analysis, the relationship between ANCA and increased
prevalence of ILD was independent of anti-Scl-70. To
our knowledge, this is the first study to find an inde-
pendent association of ANCA and ILD in SSc patients
in the absence of comorbid AAV. An association be-
tween anti-MPO antibodies and ILD in patients with
rheumatoid arthritis without comorbid AAV has been
reported in a small retrospective analysis, with 3 of 12
(25%) patients with anti-MPO antibodies manifesting ILD
compared to 0 of 85 patients without anti-MPO anti-
bodies [27]. The authors suggested subclinical vasculitis
might have led to pulmonary fibrosis in these 3 patients
[27]. For patients with SSc/AAV overlap, it is estimated
that the prevalence of ILD is around 80%, which is far
higher than that expected for each condition individually
[12, 28]. It is suggested that a high susceptibility to ILD in
patients with AAV/SSc overlap may be related to an in-
flammatory insult or due to oxidative stress caused by
ANCA in patients with a predisposition to ILD due to
their SSc [12, 28]. In our study, the underlying cause of
the association between ANCA and increased prevalence
of ILD in SSc is unclear. Our findings may suggest a
pathological role of ANCA in the development of ILD in
SSc, perhaps mediated by subclinical vasculopathy; how-
ever, it is also possible that ILD itself induces the develop-
ment of ANCA antibodies. The temporal relationship
between the development of ILD and the emergence of
ANCA was not explored in this study.
Our study demonstrates an association between
ANCA and PE, and the increased prevalence of PE was
also observed in the anti-PR3-positive compared to the
anti-PR3-negative group. Notably, in multivariable ana-
lysis, this association was independent of the presence of
Fig. 1 Kaplan-Meier curve comparing survival in the ANCA-positive and ANCA-negative patients. SSc onset refers to the date of onset of
first non-Raynaud’s manifestation. Abbreviations: ANCA anti-neutrophil cytoplasmic antibodies, SSc systemic sclerosis
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anti-phospholipid antibodies. Patients with AAV are
known to have an increased prevalence of venous
thromboembolism, particularly when AAV is active;
however, the underlying cause for this increased risk is
unknown [29]. Our findings suggest that ANCA may
have a prothrombotic effect even in the absence of AAV.
Previous studies have suggested that patients with co-
morbid SSc and AAV have a higher prevalence of over-
lap syndromes with other connective tissue diseases
[14]. Our study demonstrates that even in the absence of
AAV, ANCA-positive SSc patients have a higher preva-
lence of overlap features with another connective tissue
disease and specifically a higher prevalence of overlap
with Sjogren’s syndrome. With respect to treatments,
ANCA-positive patients were more likely to receive aza-
thioprine and anti-PR3-positive patients were more
likely to receive mycophenolate. These findings may be
attributable to the increased prevalence of ILD in these
groups. Finally, ANCA-positive status was associated
with a 1.6 fold increased hazard of mortality identifying
a subset of patients with worse prognosis. While
cause-specific mortality was not evaluated, the increased
mortality associated with ANCA may be related to ILD,
thromboembolic complications and multi-organ involve-
ment seen in overlap SSc.
To our knowledge, this is the largest study investigat-
ing the clinical associations of ANCA in SSc published
to date. This study is also strengthened by a comprehen-
sive evaluation of associations with disease features and
mortality using prospectively collected data. However,
the results need to be interpreted within the limitations
of the study design. We were unable to check for all pos-
sible confounders such as thyroid and liver disease that
are known to be associated with ANCA, as information
regarding these conditions is not collected in the cohort
study. Whilst data are collected prospectively at each an-
nual study visit, this analysis was performed retrospect-
ively, and some data were missing for some patients. In
particular, only 67.5% of patients had anti-RNA polymer-
ase III antibodies tested. However, for the remainder of
variables, the percentage missing data was below 10%.
Even though the study included a large number of pa-
tients, the overall prevalence of each of anti-PR3 and
anti-MPO was low, limiting the power of the statistical
analyses to draw robust conclusions. Lack of data on ser-
ial measurement of anti-MPO and anti-PR3 titre is also
a limitation, as is lack of confirmation of all ENA and
anti-dsDNA testing using immunoprecipitation or West-
ern blot, and the Farr radioimmunoassay, respectively.
Conclusions
This study reveals a significant association between
ANCA in SSc and ILD, pulmonary embolism, syno-
vitis and overlap syndrome with other connective
tissue diseases. Patients who are ANCA positive have
increased mortality, independent of sex or age at
diagnosis. These findings suggest that ANCA should
be tested at baseline in SSc patients as it is associated
with a worse prognosis and necessitates vigilant mon-
itoring and follow-up.
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